NovaBridge Biosciences (NBP) Total Non-Current Liabilities (2018 - 2025)

NovaBridge Biosciences (NBP) has 7 years of Total Non-Current Liabilities data on file, last reported at $29.1 million in Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $29.1 million, up 152.34% year-over-year; the trailing twelve-month figure through Dec 2025 was $29.1 million (up 152.34% YoY), and the FY2025 annual result was $29.1 million, up 152.34% from the prior year.
• Total Non-Current Liabilities rose to $29.1 million in Q4 2025 per NBP's latest filing, from $11.5 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $148.1 million in Q2 2022 and troughed at $11.5 million in Q4 2024.
• A 5-year average of $58.0 million and a median of $30.9 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities jumped 1572.79% in 2021, then tumbled 88.07% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $27.6 million in 2021, then increased by 18.25% to $32.6 million in 2022, then jumped by 48.89% to $48.6 million in 2023, then sank by 76.29% to $11.5 million in 2024, then surged by 152.34% to $29.1 million in 2025.
• Business Quant data shows NBP's Total Non-Current Liabilities at $29.1 million in Q4 2025, $11.5 million in Q4 2024, and $14.9 million in Q3 2024.